FDA Approves First Therapy for Non-cystic Fibrosis Bronchiectasis
-
By
August 12, 2025
-
2 min
-
1
Brinsupri (brensocatib) is FDA approved for non-cystic fibrosis bronchiectasis.
-
2
Targets neutrophilic inflammation, addressing disease pathophysiology.
-
3
Reduces annual exacerbation rates by more than 21%.
-
4
Most frequent adverse reactions include upper respiratory infections and hypertension.
-
5
Available through specialty pharmacies in the US, with international approvals underway.
-
The FDA has approved Brinsupri (brensocatib), the first targeted therapy for adults and adolescents with non-cystic fibrosis bronchiectasis, a condition affecting approximately 500,000 patients in the U.S. This innovative once-daily oral dipeptidyl peptidase 1 inhibitor is designed to target neutrophilic inflammation, a key factor in disease progression. Clinical trials, including Phase 3 ASPEN and Phase 2 WILLOW, demonstrated that brensocatib significantly reduces annualized exacerbation rates and improves patient outcomes.
-
1
Brinsupri (brensocatib) is FDA approved for non-cystic fibrosis bronchiectasis.
-
2
Targets neutrophilic inflammation, addressing disease pathophysiology.
-
3
Reduces annual exacerbation rates by more than 21%.
-
4
Most frequent adverse reactions include upper respiratory infections and hypertension.
-
5
Available through specialty pharmacies in the US, with international approvals underway.
Listen Tab content
